Ibrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
94.74
Gini
0.723
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ibrutinib. Strongest target: ERBB4_HER4 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 100.0% | 0.0% |
| 2 | TXK | 99.9% | 0.1% |
| 3 | BLK | 99.7% | 0.3% |
| 4 | EGFR | 99.3% | 0.7% |
| 5 | CSK | 99.3% | 0.7% |
| 6 | FGR | 99.1% | 0.9% |
| 7 | BMX_ETK | 98.9% | 1.1% |
| 8 | ERBB2_HER2 | 98.8% | 1.2% |
| 9 | BTK | 98.8% | 1.3% |
| 10 | TEC | 98.7% | 1.3% |
| 11 | JAK3 | 98.6% | 1.4% |
| 12 | LCK | 98.0% | 2.0% |
| 13 | YES_YES1 | 96.5% | 3.5% |
| 14 | BRK | 96.5% | 3.5% |
| 15 | LYN | 95.7% | 4.3% |
| 16 | HCK | 95.1% | 4.9% |
| 17 | MKK7 | 94.8% | 5.2% |
| 18 | CK2A2 | 94.7% | 5.3% |
| 19 | ITK | 94.5% | 5.5% |
| 20 | RIPK3 | 92.9% | 7.1% |
Selectivity landscape
Where Ibrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ibrutinib.
Annotations
Sign in to read and post annotations.
Loading…